At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 51 enrolled
Drug / intervention
blackcurrant (BC) extractdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Blackcurrant Modifies Gut Microbiota and Reduces the Risk of Postmenopausal Osteoporosis and Cardiovascular Disease: A Pilot Randomized Clinical Trial
In Brief
A Phase 1 clinical trial evaluating blackcurrant (BC) extract for Postmenopausal Osteoporosis and 2 related conditions. Completed, enrolled 51 participants across 1 site.
Detailed Summary
Aim to evaluate the effects of blackcurrant supplementation on changes in gut microbiome, bone mass, and CVD risk factors in adult women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartJul 20, 2021
Primary CompletionOct 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.0 years ago
Interventions
blackcurrant (BC) extractdrug
A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency